Veteran venture investor and operator focused on early-stage technology and healthcare companies, D. Garet Strange brings board-level experience, portfolio construction skills and deal-sourcing networks across the US. Prior roles span startup leadership and venture investing, with a track record of guiding exits, governance and strategic scaling. Known for active engagement in seed-to-Series A rounds, capital allocation discipline and mentorship of founding teams, typically partnering with institutional co-investors.
Veteran venture investor and operator focused on early-stage technology and healthcare companies, D. Garet Strange brings board-level experience, portfolio construction skills and deal-sourcing networks across the US. Prior roles span startup leadership and venture investing, with a track record of guiding exits, governance and strategic scaling. Known for active engagement in seed-to-Series A rounds, capital allocation discipline and mentorship of founding teams, typically partnering with institutional co-investors.
Focuses on early-stage technology and healthcare investments, prioritizing seed to Series A opportunities where founder-market fit and defensible product differentiation are clear. Employs active, board-level stewardship to accelerate go-to-market, governance and follow-on fundraising, while co-investing with institutional partners to diversify risk. Capital allocation favors concentrated, stage-weighted commitments, rigorous due diligence, and milestone-driven follow-ons. Time horizon is growth-oriented multi-year exits; risk discipline emphasizes operational KPIs, capital efficiency and repeatable business models.
Focuses on early-stage technology and healthcare investments, prioritizing seed to Series A opportunities where founder-market fit and defensible product differentiation are clear. Employs active, board-level stewardship to accelerate go-to-market, governance and follow-on fundraising, while co-investing with institutional partners to diversify risk. Capital allocation favors concentrated, stage-weighted commitments, rigorous due diligence, and milestone-driven follow-ons. Time horizon is growth-oriented multi-year exits; risk discipline emphasizes operational KPIs, capital efficiency and repeatable business models.
| Trades 2242 | Longs Won 1439/2242 64% | Profit Factor 11.26 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $268,002.97 |
| Average Win $65,095.85 | Best Trade (Oct 15) $7.69M | Sharpe Ratio -77.95 |
| Average Loss -$10,356.36 | Worst Trade (Oct 15) -$392,318.98 | Z-Score 0.68 (50.09%) |
| Commissions $0 | Avg. Trade Length 1y 5d | Expectancy $38,071.71 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 35,714 | 32,143 | 28,571 | 25,000 | 21,429 | 17,857 | 14,286 | 10,714 | 7,143 | 3,571 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 13,646 | $2.73M | $4.7M | - | $1.98M | 72.51% | +0.788% |
ABBV AbbVie Inc. | 1,609 | $267,477.3 | $459,104.01 | - | $191,626.71 | 71.64% | +0.683% |
AGG iShares Core U.S. Aggregate Bond ETF | 2,667 | $265,344.1 | $254,765.17 | - | -$10,578.93 | -3.99% | +0.121% |
AGGA Astoria Dynamic Core US Fixed Income ETF | 839,138 | $21.2M | $20.54M | - | -$657,465.59 | -3.1% | +0.041% |
ALLW SPDR Bridgewater All Weather Mutual Fund | 238,443 | $6.62M | $6.96M | - | $346,088.08 | 5.23% | +0.086% |
AMAT Applied Materials, Inc. | 972 | $180,686.36 | $409,250.88 | - | $228,564.52 | 126.5% | -2.086% |
AMP Ameriprise Financial, Inc. | 551 | $209,599.33 | $279,334.96 | - | $69,735.63 | 33.27% | +0.872% |
AMZN Amazon.com Inc | 9,502 | $1.78M | $2.41M | - | $629,981.58 | 35.44% | -0.55% |
AOA iShares Core Aggressive Allocation ETF | 12,267 | $1.1M | $1.2M | - | $98,430.64 | 8.96% | +0.113% |
ASML ASML Holding N.V. New York Registry Shares | 167 | $220,011 | $279,239.03 | - | $59,228.03 | 26.92% | +0.884% |
ATYR Atyr Pharma Inc. | 35,992 | $24,527.32 | $6,453.37 | - | -$18,073.95 | -73.69% | -2.554% |
AVGO Broadcom Inc. | 1,142 | $323,185.74 | $385,259.41 | - | $62,073.67 | 19.21% | -2.026% |
AXP American Express Company | 2,783 | $521,668.63 | $886,635.97 | - | $364,967.34 | 69.96% | +1.504% |
BAB Invesco Taxable Municipal Bond ETF | 196,857 | $5.28M | $5.07M | - | -$210,038.8 | -3.98% | -0.058% |
BAC Bank of America Corporation | 26,302 | $902,204.95 | $1.38M | - | $481,411.76 | 53.36% | +1.75% |
BBIB JPMorgan BetaBuilders U.S. Treasury Bond 3-10 Year ETF | 11,894 | $1.15M | $1.13M | - | -$21,344.61 | -1.86% | +0.106% |
BKR Baker Hughes Company | 7,539 | $458,906.18 | $420,864.67 | - | -$38,041.51 | -8.29% | +2.619% |
BRK-B Berkshire Hathaway Inc. | 1,012 | $445,666.13 | $538,115.82 | - | $92,449.69 | 20.74% | +1.152% |
BSCQ Invesco BulletShares 2026 Corporate Bond ETF | 35,469 | $689,512.41 | $693,773.64 | - | $4,261.23 | 0.62% | +0.051% |
BSCR Invesco BulletShares 2027 Corporate Bond ETF | 18,912 | $368,455.89 | $370,769.76 | - | $2,313.87 | 0.63% | +0.077% |